Peakdale and GSK extend agreement

Published: 4-Mar-2004

UK contract research company Peakdale Molecular and GlaxoSmithKline have extended their collaboration in the respiratory and inflammation area.


UK contract research company Peakdale Molecular and GlaxoSmithKline have extended their collaboration in the respiratory and inflammation area.

For the duration of 2004 Peakdale will provide a dedicated team of chemists to work with GSK's Respiratory and Inflammation Centre of Excellence for Drug Discovery (RI CEDD).

Peakdale has worked with GSK's RI CEDD since October 2002, providing synthetic chemistry services and expertise for the generation of low molecular weight drug-like compounds.

The team will be based at Peakdale's £4m headquarters in Derbyshire, which has the capacity for 15 chemistry laboratories. Currently eight labs are fully operation with 43 production chemists, including a small kilo scale facility.

  

You may also like